Revealing the changes of IgG subclass‐specific N ‐glycosylation in colorectal cancer progression by high‐throughput assay
PROTEOMICS – Clinical Applications · 2021-05 · 15 (2-3)
DOI: 10.1002/prca.202000022 ↗Kurz gefasst
Fachartikel in der Zeitschrift PROTEOMICS – Clinical Applications, online erschienen am 15.04.2021. Verfasst von Si Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Labo…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Immunoglobulin G, High-Throughput Screening Assays. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Purpose
The changes of glycosylation of different IgG subclass in colorectal cancer (CRC) were rarely investigated. The authors aimed to use a simple and high‐throughput analytical method to explore the changes of subclass‐specific IgG glycosylation in CRC, and to find the specific glyco‐biomarkers for early detection of this disease. Experimental design Serum samples from 71 cancer patients and 22 benign patients with 50 age‐ and sex‐matched healthy controls were collected from two independent cohorts. Subclass‐specific IgG glycosylation was profiled by MALDI‐MS followed by the structural identification through MALDI‐MS/MS. The exported MS data was automatically and rapidly processed by the self‐developed MATLAB code.
Results
Statistical analysis suggested the significantly decreased galactosylation and remarkably increased agalactosylation of IgG1 or IgG2 in the malignant transformation of CRC, which enables the differentiation between cancer patients and healthy controls. The changes of glycan features were elucidated by the exploration of individual glycopeptides, showing the biantennary fucosylated glycan without galactose (H3N4F1) or with two galactose (H5N4F1) of IgG1 and IgG2 could distinguish cancer group from both benign and control groups. Conclusions and clinical relevance Through the simple and high‐throughput procedures, this study revealed the important role of IgG glycopeptides in the premature pathology of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics-Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, C…
- Wuhan Institute of Biological products, Wuhan, China.
- Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Yu, Y., Liu, Y., Lin, J., Fu, Y., Cheng, L., & Liu, X. (2021). Revealing the changes of IgG subclass‐specific N ‐glycosylation in colorectal cancer progression by high‐throughput assay. PROTEOMICS – Clinical Applications, 15(2-3). https://doi.org/10.1002/prca.202000022
Vancouver
Liu S, Yu Y, Liu Y, Lin J, Fu Y, Cheng L, et al. Revealing the changes of IgG subclass‐specific N ‐glycosylation in colorectal cancer progression by high‐throughput assay. PROTEOMICS – Clinical Applications. 2021;15(2-3). doi:10.1002/prca.202000022
BibTeX
@article{Liu2021,
author = {Liu, Si and Yu, Yuting and Liu, Yuanyuan and Lin, Jiajing and Fu, Yang and Cheng, Liming and Liu, Xin},
title = {Revealing the changes of IgG subclass‐specific N ‐glycosylation in colorectal cancer progression by high‐throughput assay},
journal = {PROTEOMICS – Clinical Applications},
year = {2021},
volume = {15},
number = {2-3},
doi = {10.1002/prca.202000022}
}
EUVIMED